QuickView for CYLDI;jsessionid=AB963986402038E41312AD4FB2D7AD37;jsessionid=2972C14E444902BCE0F6514A0473FCDA;jsessionid=FE085666D9D8F49F31C17ADA5B00CB46;jsessionid=18C0E0A17138DAC27FE7111B8883BBDA (gene)

1. CYLD regulates cell ferroptosis through Hippo/YAP signaling in prostate cancer progression.
2. SPATA2 restricts OTULIN-dependent LUBAC activity independently of CYLD.
3. Impact of CYLD on chromatin structure and histone methylation in malignant melanoma.
4. Inactivation of the Tumor Suppressor CYLD Sensitizes Mice to Breast Cancer Development.
5. CYLD alleviates NLRP3 inflammasome-mediated pyroptosis in osteoporosis by deubiquitinating WNK1.

There were no clinical trials for CYLDI;jsessionid=AB963986402038E41312AD4FB2D7AD37;jsessionid=2972C14E444902BCE0F6514A0473FCDA;jsessionid=FE085666D9D8F49F31C17ADA5B00CB46;jsessionid=18C0E0A17138DAC27FE7111B8883BBDA